|Outcome||Relative effect 95%CI||LoD||Trt. better when||I2||k (RCT/OBS)||Bayesian probability||Overall ROB||Publication bias||Degree of certainty||Endpoint importance||Published MA|
|deaths||1.09 [0.78, 1.53]||< 1||0%||1 study (1/-)||30.8 %||some concern||not evaluable||moderate||crucial||-|
|Major bleeding||1.83 [0.53, 6.34]||< 1||0%||1 study (1/-)||16.9 %||some concern||not evaluable||moderate||non important||-|
|Thromboembolic events||1.07 [0.76, 1.49]||< 1||0%||1 study (1/-)||35.2 %||some concern||not evaluable||moderate||non important||-|
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.